New equatorially modified polymer linked multimers of guansine-3', 5'-cyclic monophosphates

A method of treating a human with a retinal, neuronal, or neurodegenerative disorder comprising administering an effective amount of a compound to the human in need thereof wherein the compound is selected from the group consisting of:

• (22) 8-Bromo-(4-methyl-β-phenyl-1, N2-etheno)guanosine-3′, 5′-cyclic monophosphorothioate, Rp-isomer;
• (23) 8-Bromo-(3-thiophen-yl-1, N2-etheno)guanosine-3′, 5′-cyclic monophosphorothioate, Rp-isomer;
• (24) 8-Bromo-(2-naphthyl-1, N2-etheno)guanosine-3′, 5′-cyclic monophosphorothioate, Rp-isomer;
• (32) 8-Carboxymethylthio-β-phenyl-1, N2-ethenoguanosine-3′, 5′-cyclic monophosphorothioate, Rp-isomer;
• (33) β-Phenyl-1, N2-etheno-8-phenylamidomethylthioguanosine-3′, 5′-cyclic monophosphorothioate, Rp-isomer;
• (34) 8-(4-Hydroxyphenylthio)-β-phenyl-1, N2-ethenoguanosine-3′, 5′-cyclic monophosphorothioate, Rp-isomer;
• (35) 8-(4-Isopropylphenylthio)-β-phenyl-1, N2-ethenoguanosine-3′, 5′-cyclic monophosphorothioate, Rp-isomer;
• (36) 8-(2-Aminophenylthio)-β-phenyl-1, N2-ethenoguanosine-3′, 5′-cyclic monophosphorothioate, Rp-isomer;
• (37) β-Phenyl-1, N2-etheno-8-thioguanosine-3′, 5′-cyclic monophosphorothioate, Rp-isomer;
• (39) β-(4-Azidophenyl)-1, N2-etheno-8-bromoguanosine-3′, 5′-cyclic monophosphorothioate, Rp-isomer;
• (50) 8-Phenyl-β-phenyl-1, N2-ethenoguanosine-3′, 5′-cyclic monophosphorothioate, Rp-isomer;
• (51) 8-(4-Chlorophenyl)-β-phenyl-1, N2-ethenoguanosine-3′, 5′-cyclic monophosphorothioate, Rp-isomer;
• (52) 8-(4-Chlorophenylsulfoxide)guanosine-3′, 5′-cyclic monophosphorothioate, Rp-isomer;
• and
• (54) 8-(4-Chlorophenylsulfonyl)-β-phenyl-1, N2-ethenoguanosine-3′, 5′-cyclic monophosphorothioate, Rp-isomer;
• or a pharmaceutically acceptable salt thereof.